Clinical trials: Platinum-Resistant Ovarian Cancer
Ovarian Cancer
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for…
- Trial name
- ASPENOVA (NCT07546500)
- Testing
- Investigator's choice of Chemotherapy, Azenosertib
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 420 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
This study is phase II, open label, clinical trial to determine the efficacy of Oregovomab and non-platinum chemotherapy in PARP inhibitor resistant ovarian, fallopian tube, or primary peritoneal cancer patients who were not…
- Trial name
- NCT05407584
- Testing
- Orevogomab+PLD, Orevogomab+Paclitaxel
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yonsei University
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
Bone Sarcoma, Dedifferentiated Chondrosarcoma
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer…
- Conditions
- Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone
- Trial name
- NCT03449108
- Testing
- Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer
Background: Epithelial Ovarian Cancer is the most lethal amongst the gynecologic malignancies and is the fifth leading cause of cancer death in women in the United States.1 Despite initial high response rates, 50% to 75% of women…
- Trial name
- NCT02545010
- Testing
- Paclitaxel, LDWART (Low Dose Whole Abdominal Radiation Therapy)
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- National University Hospital, Singapore
Ovarian Cancer
Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer
The purpose of this study is to to investigate the effect of tocotrienol as a nutritional supplement in combination with bevacizumab in patients with advanced ovarian cancer.
- Trial name
- Toco-Ovar (NCT02399592)
- Testing
- Bevacizumab, Tocotrinol
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- Vejle Hospital
Ovarian Cancer, Peritoneal Cancer
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
The purpose of this study is to determine the safest and maximum tolerated dosing regimens for intraperitoneal oxaliplatin with intravenous docetaxel and intravenous oxaliplatin with intraperitoneal docetaxel for recurrent…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00692900
- Testing
- intravenous docetaxel with intraperitoneal oxaliplatin, intravenous oxaliplatin with intraperitoneal docetaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Ovarian Neoplasm
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal…
- Trial name
- COHORT-A (NCT05751629)
- Testing
- Dostarlimab, Bevacizumab, Niraparib
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tesaro, Inc.
Platinum-resistant Ovarian Cancer, Endometrial Cancer
A Study of DeTIL-0255 in Adults With Advanced Malignancies
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
- Conditions
- Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT05107739
- Testing
- Drug Product De-TIL-0255
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nurix Therapeutics, Inc.
Platinum-resistant Epithelial Ovarian Cancer
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.
- Trial name
- AVALON (NCT05243524)
- Testing
- Maveropepimut-S, Cyclophosphamide 50mg
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 16 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Ovarian Cancer
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with Chemotherapy in…
- Trial name
- NCT03763123
- Testing
- Sevacizumab, Paclitaxel, Topotecan
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Ovarian Neoplasms
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This is a phase II open label, non-randomized, study to evaluate the safety and efficacy of Ipatasertib (GDC-0068) in combination with paclitaxel in platinum-resistant recurrent epithelial ovarian cancer.
- Trial name
- NCT04561817
- Testing
- Ipatasertib, Paclitaxel
- Where
- United States
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ovarian Cancer
Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)
The objective of this study is to compare progression-free survival (PFS), based upon investigator assessment using Response Evaluation Criteria In Solid Tumors version 1.0 (RECIST 1.0) and clinical findings, in participants with…
- Trial name
- PRECEDENT (NCT00722592)
- Testing
- Vintafolide, pegylated liposomal doxorubicin (PLD), EC20
- Volunteers
- 162 people
- Sponsor
- Endocyte
Ovarian Cancer
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.
- Trial name
- NCT05636111
- Testing
- Paclitaxel, Bevacizumab, Lurbinectedin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT01100372
- Testing
- gemcitabine hydrochloride, liposome-encapsulated doxorubicin citrate, quality-of-life assessment
- Where
- Austria
- Volunteers
- 154 people
- Sponsor
- Medical University Innsbruck
Ovarian Cancer
Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer
The study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy with pembrolizumab in recurrent, platinum resistant OC patients.
- Trial name
- MITO27 (NCT03539328)
- Testing
- Pembrolizumab, Gemcitabine, Paclitaxel
- Where
- Italy
- Volunteers
- 138 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer.
- Trial name
- NCT00407563
- Testing
- Bevacizumab, Abraxane
- Where
- 11 sites in United States
- Volunteers
- 48 people
- Sponsor
- Accelerated Community Oncology Research Network
Recurrent Ovarian Cancer, Platinum Resistance
Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study
This trial was designed as a single-arm, open-label, prospective clinical trial to evaluate the efficacy (ORR) and safety (AE incidence) of CapsuleX in combination with cisplatin for platinum-resistant recurrent ovarian cancer…
- Trial name
- NCT07495384
- Testing
- CapsuleX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
- Trial name
- NCT06730347
- Testing
- Lorigerlimab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- MacroGenics
Ovarian Neoplasms
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
Regorafenib is an oral multikinase inhibitor that blocks the activity of kinases involved in angiogenesis (VEGFR 1,2,3 and TEK), oncogenesis (KIT, Ret Proto-Oncogene (RET), Raf-1 Proto-Oncogene, Serine/Threonine Kinase (RAF1) and…
- Trial name
- NCT02736305
- Testing
- Regorafenib
- Where
- Singapore
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore